Product Information

CAS No.	54863-37-5
Product Name	Dapansutrile

Biological Targets

NLRP3

Associated Conditions

COVID-19·melanoma·type 2 diabetes mellitus·Schnitzler syndrome·myocardial infarction·

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson's disease.

Journal of neuroinflammation • Vol. 20, Issue 1 • 2023

PMID: 37349821 PMC: PMC10286423 DOI: 10.1186/s12974-023-02830-w

Dapansutrile ameliorated chondrocyte inflammation and osteoarthritis through suppression of MAPK signaling pathway.

Human & experimental toxicology • Vol. 41 • 2022

PMID: 36508695 DOI: 10.1177/09603271221145401

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.

The Lancet. Rheumatology • Vol. 2, Issue 5 • 2020

PMID: 33005902 PMC: PMC7523621 DOI: 10.1016/s2665-9913(20)30065-5

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020

PMID: 32020584 PMC: PMC7160657 DOI: 10.1111/imm.13175

Products
- CDMO Compounds
- API & Candidates
Services
CDMO & Manufacturing
Custom Synthesis
Process Development
Lab To Pilot
Commercialization
Generic APIs
CRO
Preclinical
Pharmacology & Efficacy
DMPK & Bioanalysis
Toxicology & Safety
Disease Models
Technologies
High-Potent
Chiral Synthesis
Cloud Synthesis
Fermentation
Flow Chemistry
Biocatalysis
Support
Regulatory Support
Supply Chain Solutions
About
Perspectives
Contact

HomeHome
ProductsProducts
Bioactive CompoundsBioactive Compounds
Immunology & InflammationImmunology & Inflammation
NLRNLR
DapansutrileDapansutrile

Dapansutrile

CAS No.	54863-37-5
MDL No.	MFCD11934305
MF	C₄H₇NO₂S
MW	133.17
InChI Key	LQFRYKBDZNPJSW-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT→

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	54863-37-5
Product Name	Dapansutrile

Biological Targets

NLRP3

Associated Conditions

COVID-19·melanoma·type 2 diabetes mellitus·Schnitzler syndrome·myocardial infarction·

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson's disease.

Journal of neuroinflammation • Vol. 20, Issue 1 • 2023

PMID: 37349821 PMC: PMC10286423 DOI: 10.1186/s12974-023-02830-w

Dapansutrile ameliorated chondrocyte inflammation and osteoarthritis through suppression of MAPK signaling pathway.

Human & experimental toxicology • Vol. 41 • 2022

PMID: 36508695 DOI: 10.1177/09603271221145401

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.

The Lancet. Rheumatology • Vol. 2, Issue 5 • 2020

PMID: 33005902 PMC: PMC7523621 DOI: 10.1016/s2665-9913(20)30065-5

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020

PMID: 32020584 PMC: PMC7160657 DOI: 10.1111/imm.13175

Your Partner for
Complex Chemistry

About Us
Perspectives
Products
Contact

Preclinical Development
Technologies
Custom Synthesis

Ready to start your project?

Provide your target molecule or project specifications to align on a tailored development and scale-up pathway with our scientific team.

START A PROJECT

Westerstraat 10, 3016 DH, Rotterdam, The Netherlands

All products are supplied strictly for research and development use only and are not intended for human or veterinary administration, diagnostic use, or therapeutic use. Preclinical and related services are provided solely for research and development purposes and do not constitute clinical diagnosis, treatment, or veterinary care.

CLIENT PORTAL|TERMS AND CONDITIONS|PRIVACY POLICY|

Dapansutrile

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Dapansutrile

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Documentation

Dapansutrile

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Related Articles

Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson's disease.

Dapansutrile ameliorated chondrocyte inflammation and osteoarthritis through suppression of MAPK signaling pathway.

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Dapansutrile

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Related Articles

Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson's disease.

Dapansutrile ameliorated chondrocyte inflammation and osteoarthritis through suppression of MAPK signaling pathway.

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Documentation